Growing experience with mTOR inhibitors in pediatric solid organ transplantation

Pediatric Transplantation

Volumn 17, Issue 7, 2013, Pages 694-706

  Ganschow, R ^a   Pape, L ^b   Sturm, E ^c   Bauer, J ^d   Melter, M ^e   Gerner, P ^f   Hocker B ^a   Ahlenstiel, T ^b   Kemper, M ^a   Brinkert, F ^a   Sachse, M M ^g   Tonshoff B ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g Klinikum Bremerhaven Reinkenheide   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

calcineurin inhibitors; children; pediatric; sirolimus; transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; BK VIRUS INFECTION; CYTOMEGALOVIRUS INFECTION; DELAYED PUBERTY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EPSTEIN BARR VIRUS INFECTION; FIBROSIS; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY METASTASIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WOUND HEALING IMPAIRMENT;

CALCINEURIN INHIBITORS; CHILDREN; PEDIATRIC; SIROLIMUS; TRANSPLANTATION;

CALCINEURIN; CHILD; FIBROSIS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; RISK; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; WOUND HEALING;

EID: 84885431351     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12147     Document Type: Article

References (86)

1. Mahalati K, Kahan BD,. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001: 40: 573-585.
2. Kirchner GI, Meier-Wiedenbach I, Manns MP,. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004: 43: 83-95.
3. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M,. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999: 27: 627-632.
4. R apamune ®. Summary of Product Characteristics. New York: Pfizer, Last updated 2011.
5. C ertican ®. Basic Prescribing Information. Basel, Switzerland: Novartis Pharma AG, 2012.
6. Zimmerman J, Kahan BD,. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997: 37: 405-415.
7. Nashan B,. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002: 11: 1845-1857.
8. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C,. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002: 42: 95-99.
9. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A,. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006: 38: 3456-3458.
10. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008: 30: 113-116.
11. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004: 77: 244-251.
12. Wu FL, Tsai MK, Chen RR, et al. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy 2005: 25: 646-653.
13. Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R, for the Everolimus Pediatric Study Group. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study. Pediatr Transplant 2013: 17: 237-243.
14. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010: 10: 2349-2354.
15. Pape L, Lehner F, Blume C, Ahlenstiel T,. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011: 92: 658-662.
16. Benfield MR, Bartosh S, Ikle D, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010: 10: 81-88.
17. Macdonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008: 8: 984-989.
18. Kanzelmeyer NK, Ahlenstiel T, Drube J, et al. Protocol biopsy-driven interventions after pediatric renal transplantation. Pediatr Transplant 2010: 14: 1012-1018.
19. Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 2008: 12: 456-463.
20. Harmon W, Meyers K, Inglefinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006: 17: 1735-1745.
21. Blydt-Hansen TD, Gibson IW, Birk PE,. Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study. Pediatr Transplant 2010: 14: 909-918.
22. Höcker B, Feneberg R, Köpf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006: 10: 593-601.
23. Pape L, Ahlenstiel T, Ehrich JH, Offner G,. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007: 11: 291-295.
24. Filler G, Womiloju T, Feber J, Lepage N, Christians U,. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005: 5: 2005-2010.
25. Iorember FM, Patel HP, Ohana A, et al. Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis. Pediatr Transplant 2010: 14: 93-99.
26. Monteverde ML, Ibañez J, Balbarrey Z, Chaparro A, Diaz M, Turconi A,. Conversion to sirolimus in pediatric renal transplant patients: A single-center experience. Pediatr Transplant 2012: 16: 82-88.
27. Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA,. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008: 12: 773-777.
28. Ibañez JP, Monteverde ML, Goldberg J, Diaz MA, Turconi A,. Sirolimus in pediatric renal transplantation. Transplant Proc 2005: 37: 682-684.
29. Halim MA, Al-Otaibi T, Johny KV, et al. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: A single center experience. Transplant Proc 2009: 41: 1666-1670.
30. Powell HR, Kara T, Jones CL,. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007: 22: 1773-1777.
31. Garcia CD, Bittencourt VB, Alves AB, et al. Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 2006: 38: 1901-1903.
32. Prates LC, Pereira LM, Belangero VMS, Mazzali M,. Sirolimus in pediatric renal transplantation. Am J Transplant 2012: 12 (Suppl 3): Abstract 1413.
33. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 474-478.
34. Weintraub L, Li L, Kambham N, et al. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 2008: 12: 541-549.
35. Basso MS, Subramaniam P, Tredger M, et al. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients. Pediatr Transplant 2011: 15: 722-727.
36. Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B, Ganschow R,. The use of everolimus in pediatric liver transplant recipients: First experience in a single center. Pediatr Transplant 2011: 15: 510-514.
37. Sturm E, Handgretinger R, Königsrainer A, Nadalin S,. Pediatric liver transplantation: Single centre experience with CNI-free immunosuppression. Transpl Int 2011: 24 (Suppl 3): 20.
38. Gibelli NE, Tannuri U, Pinho-Apezzato ML, et al. Sirolimus in pediatric liver transplantation: A single-center experience. Transplant Proc 2009: 41: 901-903.
39. Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP,. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004: 8: 362-366.
40. Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL,. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004: 8: 243-248.
41. Markiewicz M, Kalicinski P, Teisseyre J, Ismail H, Kaminski A, Teisseyre M,. Rapamycin in children after liver transplantation. Transplant Proc 2003: 35: 2284-2286.
42. Lehmkuhl HB, Schubert S, Dandel M, et al. Everolimus in pediatric heart transplantation: Report on efficacy, pharmacokinetics and safety in infants below the age of 1 year. J Heart Lung Transplant 2009: 28 (2 Suppl): S234.
43. Chinnock TJ, Shankel T, Deming D, et al. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients. Pediatr Transplant 2011: 15: 746-749.
44. Schweiger M, Dandel M, Hiemann N, et al. Efficacy and safety of immunosuppression with everolimus in pediatric heart transplantation. Eur Surg 2011: 43 (Suppl): 16.
45. Vazquez-Alvarez MC, Camino-Lopez M, Medrano-Lopez C, et al. Everolimus in pediatric heart transplantation: A Spanish center experience. J Heart Lung Transplant 2011: 30 (4 Suppl S): S221.
46. Behnke-Hall K, Bauer J, Thul J, et al. Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatr Transplant 2011: 15: 784-789.
47. Schubert S, Lehmkuhl HB, Huebler M, Hetzer R, Berger F,. Comparison of de novo everolimus, AZA and MMF in cyclosporine based immunosuppressive protocol in pediatric heart transplant patients. J Heart Lung Transplant 2010: 29 (2 Suppl S): S107.
48. Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E,. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010: 14: 402-408.
49. Carducci FIC, Grutter G, D'argenio P, Parisi F,. Use of everolimus in pediatric patients after heart transplantation: A single center experience. J Heart Lung Transplant 2009: 28 (2 Suppl): S234.
50. Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR,. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006: 25: 518-522.
51. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI,. Sirolimus immunosuppression in pediatric heart transplant recipients: A single-center experience. J Heart Lung Transplant 2005: 24: 184-189.
52. Brinkert F, Kemper MJ, Briem-Richter A, Van Husen M, Treszl A, Ganschow R,. High prevalence of renal dysfunction in children after liver transplantation: Non-invasive diagnosis using a cystatin C-based equation. Nephrol Dial Transplant 2011: 26: 1407-1412.
53. Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006: 148: 475-480.
54. Ruebner RL, Reese P, Denburg MR, et al. Risk factors for end-stage kidney disease after pediatric liver transplantation. Am J Transplant 2012: 12: 3398-3405.
55. Harambat J, Ranchin B, Dubourg L, et al. Renal function in pediatric liver transplantation: A long-term follow-up study. Transplantation 2008: 86: 1028-1034.
56. Schena FP, Pascoe MD, Alberu J, et al. Sirolimus Convert Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009: 87: 233-242.
57. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009: 9: S1-S155.
58. Wang SS, Chou NK, Chi NH, et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. Transplant Proc 2008: 40: 2607-2608.
59. Srivastava A, Muruganandham K, Vinodh PB, et al. Post-renal transplant surgical complications with newer immunosuppressive drugs: Mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol 2010: 42: 279-284.
60. Hymes LC, Warshaw BL,. Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant 2011: 15: 570-572.
61. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009: 9: 1876-1885.
62. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011: 11: 2453-2462.
63. Behnke-Hall K, Bauer J, Thul J, Logeswaran T, Horn M, Schranz D,. Outcome of renal function one year after discontinuation of everolimus. J Heart Lung Transplant 2011: 30 (40 Suppl S): S221.
64. Fasolo A, Sessa C,. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012: 18: 2766-2777.
65. Pape L, Ganschow R, Ahlenstiel T,. Everolimus in pediatric transplantation. Curr Opin Organ Transplant 2012: 17: 515-519.
66. Rangel GA, Ariceta G,. Growth failure associated with sirolimus: Case report. Pediatr Nephrol 2009: 24: 2047-2050.
67. Gonzalez D, Garcia CD, Azocar M, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 2011: 26: 961-966.
68. Billing H, Burmeister G, Plotnizki L, et al. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients. Transpl Int 2013: 26: 903-909.
69. Vilalta R, Lara E, Alvaro M, et al. MTOR and CNI without steroids in the maintenance of kidney transplanted children. Pediatr Transplant 2011: 15 (Suppl 1): 410.
70. Cavanaugh TM, Schoenemen H, Goebel J,. The impact of sirolimus on sex hormones in male adolescent kidney recipients. Pediatr Transplant 2012: 16: 280-285.
71. Tondolo V, Citterio F, Panocchia N, et al. Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 2005: 37: 1915-1917.
72. Lee S, Coco M, Greenstein SM, Schechner RS, Tellis VA, Glicklich DG,. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant 2005: 19: 162-167.
73. Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004: 4: 1084-1088.
74. Nashan B, Citterio F,. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature. Transplantation 2012: 94: 547-561.
75. Dantal J, Berthoux F, Moal M-C, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010: 23: 1084-1093.
76. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J,. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006: 45: 786-796.
77. Zhu J, Wu J, Frizell E, et al. Rapamycin inhibits stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999: 117: 1198-1204.
78. Patsenker E, Schneider V, Ledermann M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011: 55: 388-398.
79. Asthana S, Toso C, Meeberg G, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011: 25: 28-34.
80. McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011: 11: 2379-2387.
81. Ettenger RB, Grimm EM,. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001: 38 (Suppl 2): S22-S28.
82. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003: 75: 2082-2085.
83. Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
84. Höcker B, Tönshoff B,. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: A viable option? Paediatr Drugs 2011: 13: 49-69.
85. Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005: 5: 1430-1436.
86. Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001: 72: 851-855.